<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is AI-native drug discovery?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "AI-native drug discovery integrates artificial intelligence as a core component from the start, using foundation models, active learning, and lab-in-the-loop automation to design and validate therapeutics autonomously rather than adding ML as a tool to traditional workflows.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "Where does AI actually deliver value in drug discovery?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "AI delivers ROI by automating routine decision-making and data synthesis—hit prioritization, protein design optimization, retrosynthetic planning, and experimental management—not the headline-grabbing protein binding prediction that rarely blocks real campaigns.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "What is lab-in-the-loop machine learning?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Lab-in-the-loop ML creates closed-loop systems where experimental data directly informs model updates, enabling autonomous optimization through cycles of computational design, robotic synthesis, experimental validation, and model retraining.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "Should we invest in AI drug discovery?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, if you focus on automating decision-making bottlenecks and data synthesis rather than headline-grabbing capabilities like binding prediction; ROI comes from accelerating existing workflows, not replacing medicinal chemistry expertise.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "What's the ROI of foundation models in pharma?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Foundation models deliver ROI through transfer learning that reduces training data requirements, embedding-based property prediction that accelerates screening, and naturalness scoring that improves candidate prioritization, not through de novo design alone.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "When should biotech companies build vs. buy AI capabilities?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Build when your therapeutic modality or target space requires custom models (novel antibody formats, rare protein families); buy or partner for general capabilities like retrosynthesis, standard antibody optimization, or small molecule property prediction.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "How do protein language models work?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Protein language models use transformer architectures trained on millions of protein sequences via masked language modeling to learn evolutionary patterns, structural constraints, and functional relationships encoded in sequence space without explicit structural supervision.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "What are the limitations of AlphaFold for antibody design?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "AlphaFold struggles with CDR H3 loop prediction for sequences distant from PDB training data (RMSD ~4Å for novel sequences), predicts bound conformations by default when unbound structures are needed, and lacks accuracy for antibody-antigen interface modeling.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "How accurate is antibody structure prediction in 2025?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "General models achieve ~2Å RMSD on sequences similar to PDB data but degrade to 4-6Å for novel CDR H3 loops; specialized antibody models (Ibex, IgFold) handle bound/unbound states better but still struggle with out-of-distribution sequences.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "What is discrete Walk-Jump Sampling?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Walk-Jump Sampling combines local exploration via discrete diffusion (walk steps) with global jumps that escape local optima, operating natively in discrete sequence space to generate high-quality, diverse protein sequences without continuous relaxation.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "How do I get started in BioML research?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Build strong fundamentals in CS, applied math, and ML (1-2 years), complete one meaningful research project (1 year), develop engineering discipline with documented code, demonstrate high agency by identifying problems independently, and network proactively before job searching.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "Should I do a PhD for BioML work?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "A PhD helps for research-focused roles but isn't required; what matters is completing meaningful projects, demonstrated execution ability, strong engineering practices, and problem-solving agency—skills you can build through industry, self-study, or formal education.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "Which biotech companies are truly AI-native?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "AI-native biotechs build discovery platforms where ML is core to operations from day one (autonomous design loops, continuous learning systems, data-first infrastructure) with value propositions impossible to articulate before ChatGPT (Nov 2022), typically built by teams under 30 people before scaling.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "Can established biotech companies become AI-native?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No—companies that scaled before November 2022 are structurally 'AI-encumbered' by organizational inertia, incompatible systems, and established hierarchies; true AI-native transformation requires rebuilding from foundations, not rebranding or adding computational teams.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "Why do most enterprise AI transformations fail?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "MIT's NANDA initiative found 95% of enterprise GenAI pilots fail to increase revenue not due to AI technology limitations, but because of organizational learning gaps, incompatible existing systems, cultural resistance, and attempting to bolt AI onto established workflows rather than redesigning processes.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "What happened to the AI drug discovery hype?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Hype focused on solving wrong problems (binding prediction) that don't block real campaigns; value comes from unglamorous automation of routine decision-making, data synthesis, and process optimization that experienced drug hunters recognize as actual bottlenecks.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    },
    {
      "@type": "Question",
      "name": "How do you validate AI-designed antibodies?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Validation requires computational filtering (structure prediction, binding prediction, developability), experimental screening (binding affinity, specificity, expression), and functional assays (neutralization, cell-based assays) in lab-in-the-loop workflows that inform model retraining.",
        "author": {
          "@type": "Person",
          "name": "Nathan C. Frey",
          "url": "https://ncfrey.github.io"
        }
      }
    }
  ],
  "about": {
    "@type": "Thing",
    "name": "AI Drug Discovery",
    "description": "Artificial intelligence and machine learning applications in pharmaceutical drug discovery, therapeutic antibody design, and protein engineering"
  },
  "author": {
    "@type": "Person",
    "name": "Nathan C. Frey",
    "jobTitle": "CTO & Co-Founder",
    "worksFor": {
      "@type": "Organization",
      "name": "Coefficient Bio"
    },
    "url": "https://ncfrey.github.io",
    "sameAs": [
      "https://www.linkedin.com/in/ncfrey/",
      "https://scholar.google.com/citations?user=IMUja60AAAAJ"
    ]
  },
  "datePublished": "2025-10-21",
  "dateModified": "2025-10-21"
}
</script>
